MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial

WEST CHESTER, Pa.–(BUSINESS WIRE)–Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE (177Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors. This US based, Phase I clinical trial will evaluate the safety and dosimetry of EBTATE. EBTATE is a patented peptide targeting radiotherapeutic drug. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine t
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.